ProCE Banner Activity

Adapting to the Evolving Treatment Landscape for Multiple Myeloma

Clinical Thought
How are you managing your patients with multiple myeloma? Read this commentary for insight into the evolving treatment landscape.

Released: December 07, 2021

Expiration: December 06, 2022

No longer available for credit.

Share

Faculty

Brian G. M. Durie

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

S. Vincent Rajkumar

S. Vincent Rajkumar, MD

Professor of Medicine
Chair, Myeloma Amyloidosis Dysproteinemia Group
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Oncopeptides

Pfizer, Inc.

Sanofi Genzyme

Partners

International Myeloma Foundation

ProCE Banner

Program Director Disclosure

Program Director

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda and fees from non-CME/CE services from Amgen.

Faculty Disclosure

Primary Author

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received consulting fees from GlaxoSmithKline and Oncopeptides and funds for research support from Amgen, Janssen, Sanofi, and Seattle Genetics.

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, and Sanofi.

S. Vincent Rajkumar, MD

Professor of Medicine
Chair, Myeloma Amyloidosis Dysproteinemia Group
Mayo Clinic
Rochester, Minnesota

S. Vincent Rajkumar, MD, has no relevant conflicts of interest to report.

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, SecuraBio, and Takeda.